Eduardo Osinaga
Eduardo Osinaga, MD, PhD
Laboratorio de glicobiología e inmunología tumoral
- PhD en Ciencias Biológicas. Título de la tesis: “Etude de glycoprotéines associées aux carcinomes a l’aide d’anticorps monoclonaux. Caractérisation moléculaire, structure de l’epitope et interet diagnostique de l’antigène 83D4”, Universidad de Tecnología de Compiegne, Francia (1992).
- Master en Biotecnología. Especialidad: “Ingeniería enzimática, bioconversión y microbiología”, Universidad de Tecnología de Compiegne, Francia (1989).
- Doctor en Medicina, Facultad de Medicina, Udelar, Uruguay (1984).
- Inmunología
- Glicobiología
- Oncología
- Biotecnología
- Berois N, Pittini A, Osinaga E. Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives. Cancers.; 14:645. https://doi.org/10.3390/cancers14030645 (2022)
- Freire T, Landeira M, Giacomini C, Festari MF, Pittini Á, Cardozo V, Brosque A, Monin L, da Costa V, Faral-Tello P, Robello C, Osinaga E. Trypanosoma cruzi-Derived Molecules Induce Anti-Tumour Protection by Favouring Both Innate and Adaptive Immune Responses. Int J Mol Sci. 23:15032 (2022)
- Castro A, Berois N, Malanga A, Ortega C, Oppezzo P, Pristch P, Mombrú AW, Osinaga E, Pardo H. Docetaxel in chitosan-based nanocapsules conjugated with an anti-Tn antigen mouse/human chimeric antibody as a promising targeting strategy of lung tumors. International Journal of Biological Macromolecules 182:806-814 (2021)
- Berriel E, Freire T, Chiale C, Rodríguez E, Morón G, Fernández-Graña G, Crispo M, Berois N, Osinaga E. Human hydatid cyst fluid induced therapeutic anti-cancer immune responses via NK1.1 cell activation in mice. Cancer Immunology Immunotherapy 70:3617-3627 (2021)
- da Costa V, van Vliet SJ, Carasi P, Frigerio S, García PA, Croci DO, Festari MF, Costa M, Landeira M, Rodríguez-Zraquia SA, Cagnoni AJ, Cutine AM, Rabinovich GA, Osinaga E, Mariño KV, Freire T. The Tn antigen promotes lung tumor growth by fostering immunosuppression and angiogenesis via interaction with Macrophage Galactose-type lectin 2 (MGL2). Cancer Lett. 518:72-81 (2021)
- Fernandez E, Ubillos L, Elgul N, Festari MF, Mazal D, Pritsch O, Alonso I, Osinaga E, Berois N. Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer. Cancers (Basel). 13:5616. (2021)
- Festari MF, Trajtenberg F, Berois N, Pantano S, Revoredo L, Kong Y, Solari-Saquieres P, Narimatsu Y, Freire T, Bay S, Robello C, Bénard J, Gerken TA, Clausen H, Osinaga E. Revisiting the human polypeptide GalNAc-T1 and T13 paralogs. Glycobiology 27:140-153 (2017)
- Ubillos L, Freire T, Berriel E, Chiribao ML, Chiale C, Festari MF, Medeiros A, Mazal D, Rondán M, Bollati-Fogolín M, Rabinovich GA, Robello C and Osinaga E. Trypanosoma cruzi extracts elicits protective immune response against chemically-induced colon and mammary cancers.
Int J Cancer 138:1719-31 (2016) - García E, Tiscornia I, Libisch G, Trajtenberg F, Bollati-Fogolín M, Rodríguez E, Noya V, Chiale C, Brossard N, Robello C, Santiñaque F, Folle G, Osinaga E and Freire T. MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells. Int. J. Oncol. 48:2113-23 (2016)
- Sedlik C, Heitzmann A, Viel S, Ait Sarkouh R, Batisse C, Schmidt F, De La Rochere P, Amzallag N, Osinaga E, Oppezzo P, Pritsch O, Sastre-Garau X, Hubert P, Amigorena S, Piaggio E. Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen. Oncoimmunology. 5:e1171434 (2016)